Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas
  
Bristol places big bet on BioNTech's PD-L1xVEGF bispecific candidate • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Therapy Areas